| |
What's New At Atlantic Coast Vet:
Expanded Hours For Surgery Service
The surgery service at Atlantic Coast Veterinary Specialists is pleased to announce an expanded appointment schedule.
Dr. Karyn Maxworthy, Diplomate ACVS, and Dr. Robert Gilley, Diplomate ACVS, are now available for consultations Monday through Saturday including Wednesday evenings. We will continue to offer a full range of surgical services, including soft tissue, orthopedic, and neurologic procedures.
|
|
Karyn Maxworthy,
DVM, MS,
Diplomate ACVS |
| |
|
|
Robert S. Gilley,
DVM, PhD,
Diplomate ACVS |
ACVS is proud to have a full-service surgery department, including two complete surgical suites with state-of-the-art anesthetic monitoring capabilities. Our surgery team can tackle the most challenging cases in the fields of orthopedic, thoracic, gastrointestinal, oncologic, and urologic surgery. We are also available for Penn Hip evaluations and are performing the new Tightrope stabilization for cranial cruciate tears. This technique is an improvement on the traditional lateral suture and may be a less invasive option for large dogs when compared to the TPLO or the TTA.
The surgeons work in conjunction with our veterinarians in cardiology, internal medicine, oncology, and emergency medicine to provide pets with the most comprehensive care possible. We are looking forward to providing comprehensive surgical care for our referring veterinarians and welcome phone consultations at anytime.
Dr. Sikorski On: Canine Immune Mediated Hemolytic Anemia
 |
|
Lauren E.
Sikorski, DVM |
|
On Tuesday, Sept. 22, Lauren E. Sikorski, DVM gave a lecture on "Canine Immune Mediated Hemolytic Anemia" at Atlantic Coast Veterinary Specialists to an audience of
veterinarians and their staffs.
Dr. Sikorski is the newest member of the internal medicine team at Atlantic Coast Veterinary Specialists.
The lecture was sponsored in part by Abbott Laboratories.
 Click
here for her Powerpoint presentation |
 |
 |
More Drugs Available To Pets With Cancer
Recently Pfizer Animal Health announced that the FDA had approved the first canine cancer therapy in the U.S.-- Palladia (toceranib
phosphate) -- which was developed by Pfizer to treat mast cell tumors in dogs.
Until the development of Palladia, veterinarians had to rely on human cancer drugs without knowing the dosage, safety, or effectiveness in animals.
While surgery is the first line of treatment for dogs with mast cell tumors, many dogs don't have that option. The malignant tumor accounts for about 20% of skin cancer in dogs. It strikes
all breeds but is often found in Labradors, boxers, and Boston terriers.
About 60% of dogs older than six are diagnosed with cancer, and nearly half the deaths in pets older than 10 result from the disease, according to the Pet Cancer Foundation.
Palladia joins a growing list of FDA-approved drugs developed specifically for companion animals. Within the last two years, the FDA has approved three other drugs developed by Pfizer's veterinary
division: Slentrol for obesity, Cerenia for motion sickness, and Convenia, the first single-dose injected antibiotic for skin infections in dogs and cats. Novartis, Eli Lilly, and other pharmaceutical
giants are also making medicines for companion animals.
|
|
 |
|
|
Funny Bones
Pooches That'll Make You Smile:
Home From The War!
His dogs greeting him after returning from 14 months in Iraq. God bless all of those defending us abroad. And their dogs waiting for them patiently at home! [Be sure to turn up your speaker!]
|
Events Calendar (Oct.-Nov.)
Oct. 1-4
New York State Veterinary Conference
Cornell University College of
Veterinary Medicine
Ithaca, New York
Thursday, Oct. 8
LIVMA monthly meeting
Oct. 12-15
Atlantic Coast Veterinary Conference
Atlantic City Convention Center
Atlantic City, New Jersey
Oct. 14
Suffolk County Community College
Veterinary Science Technology Students
8:30-10:45 AM lecture
Dr. Kramer on "Arrhythmias"
Click here for other state, national, and global veterinary events in October.
Nov. 6-9
CVC 2009
San Diego Convention Center
San Diego, California
Thursday, Nov. 12
LIVMA monthly meeting
Click here for other state, national, and global veterinary events in November. |
About Atlantic Coast
Veterinary Specialists
At Atlantic Coast Veterinary Specialists, our commitment is to provide you — the referring veterinarian — and your clients, the best and the latest in modern veterinary medicine.
Whether it is through our mobile ultrasound service or through our referral and emergency services available, Atlantic Coast Veterinary Specialists is here to work with you as a partner on those difficult and challenging cases. We look forward to hearing from you.
Please feel free to call any member
of our Board Certified staff for help and assistance.
|
|
| |
|
| |
 |
|
Veterinary Drug Manufacturer Shut Down For Violations
The nation's largest manufacturer of generic animal drugs was recently shut down by the FDA.
The FDA filed an injunction against Teva Animal Health Inc. on July 31, prohibiting the company from manufacturing and distributing veterinary drugs until it complies with the current Good Manufacturing Practice and receives FDA approval. The agency had found significant violations of manufacturing standards at the company's facility in Missouri over the last two years.
Teva Animal Health produces and distributes drugs for dogs, horses, and livestock, including antibiotics and flea and tick shampoos. The company also sells dermatological products under the brand name DVM Pharmaceuticals.
Under the terms of the legal action, Teva Animal Health cannot resume its operations until an independent expert certifies that its facilities comply with manufacturing standards. The company said it had begun corrective actions immediately. Should the company fail to comply with regulations after it resumes operations, the FDA could order it to stop producing animal drugs altogether.
The injunction also threatens the company's principals with fines of $20,000 per day if they fail to comply with standards in the future.
Imulan To Initiate Trials For Atopic Dermatitis In Dogs
Imulan BioTherapeutics, LLC is preparing to commence with regulated trials to complete work on the T-Cell Receptor peptide immunomodulator for atopic dermatitis in dogs.
Canine atopic dermatitis is a very prevalent condition in dogs, thought to affect up to 5% of the dog population. Clinical signs of atopic dermatitis include pruritus and an increase in topical skin infections, such as staphylococcal pyoderma. The T-Cell Receptor peptides have previously shown significant improvement in dogs with severe atopic dermatitis.
T-Cell Receptor peptides target T-helper cells, immune cells that are key players in atopic and allergic dermatitis. T-helper cells are central regulators of immune function and their imbalance is implicated in a variety of disorders, including atopy, asthma, stomatitis, and various infections.
"We are excited to begin our final phase of work that will be used in support of a product approval," says Dr. Daniel Gingerich, CSO of IMULAN. "We are currently setting up multiple centers around the country to participate in our clinical program and to help acquire the necessary data for submission."
Study Looks At Flea Susceptibility To Imidacloprid
Fleas are as susceptible now to the insecticide imidacloprid as they were in 2001, according to data presented at an international veterinary parasitology conference in Canada.
According to the study's sponsor, Bayer Animal Health, data were drawn from 1,014 analyzed samples of flea eggs collected from more than 100 U.S. veterinary clinics as well as veterinary hospitals in Germany, France, and the U.K., as part of a unique Flea Susceptibility Monitoring Program. Veterinarians participating in the collection of samples sent them to two participating laboratories in California and Alabama.
While 13 flea isolates were identified from the samples, ultimately none were considered less susceptible to imidacloprid upon further investigation, the company reports.
The Flea Susceptibility Monitoring program is run by 15 veterinary parasitologists, entomologists, molecular biologists, and Bayer staff members.
"Ten years after the initiation of the Flea Susceptibility Monitoring program, our efforts remain a unique and important strategy for assessing the continuing efficacy of imidacloprid against fleas," says Dr. Byron Blagburn at Auburn University's veterinary college. "Monitoring the performance of current agents like imidacloprid is necessary to help maintain a longer viable product life for these products."
|
|
 |
|
